Glycopyrrolate

Notice of Allowance strengthens PulmoSIM's therapeutic portfolio while validating VeriSIM Life's platform for advancing therapeutics from design to the clinic. SAN FRANCISCO, CA, UNITED STATES, August 12, 2026 / EINPresswire.com / -- PulmoSIM Therapeutics LLC, a wholly owned subsidiary of VeriSIM Life, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/025,563, entitled "Compositions and Methods for Treating or Preventing Pulmonary Hypertension." The allowance provides foundational protection for PT001, PulmoSIM's lead inhaled therapeutic candidate, and represents an important milestone for both PulmoSIM's growing therapeutic portfolio and VeriSIM Life's integrated AI and biosimulation platform. The Notice of Allowance confirms that the USPTO has completed substantive examination and determined the application satisfies the requirements for patentability. The patent strengthens PulmoSIM's intellectual property estate supporting PT001 and complements additional pending applications covering pulmonary fibrosis, dry powder inhalation formulations, and related therapeutic innovations. "This patent allowance is an important validation of both our therapeutic strategy and the technology platform behind it," said Dr. Jo Varshney, Founder and Chief Executive Officer of VeriSIM Life and PulmoSIM Therapeutics. "PT001 demonstrates how combining mechanistic biology, explainable AI, and strong intellectual property can accelerate the development of differentiated medicines while creating long-term value. We believe the future of drug development belongs to platforms that reduce uncertainty and improve development efficiency from design to the clinic." PT001 is a first-in-class inhaled small molecule designed to maximize drug exposure within the lungs while minimizing systemic exposure. The program is being developed for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH ILD), and other pulmonary diseases with significant unmet medical need. Across multiple preclinical studies, PT001 has demonstrated improvements in pulmonary vascular remodeling, pulmonary vascular resistance, right ventricular function, and biomarkers associated with disease progression, while also reversing established fibrosis in pulmonary fibrosis models. “The strength of PT001 comes from a mechanistic understanding of the disease, not simply from screening for an effect,” said Dr. Vivek Gupta, Scientific Co-Founder of PulmoSIM Therapeutics. “By integrating pulmonary biology with BIOiSIM’s predictive AI and mechanistic reasoning, we were able to identify a differentiated therapeutic approach and build a clearer path from scientific insight to clinical translation.” PT001 was designed and advanced using VeriSIM Life's BIOiSIMⓇ platform, which integrates mechanistic biosimulation with explainable artificial intelligence to predict pharmacokinetics, efficacy, safety, and human clinical translation. The program demonstrates how BIOiSIM can help generate, optimize, and advance proprietary therapeutic assets while increasing confidence in development decisions before clinical testing. The patent allowance further strengthens PulmoSIM's position as it advances PT001 toward first-in-human studies while reinforcing VeriSIM Life's strategy of combining a commercial AI platform with internally developed therapeutics. Together, the two companies are building a model in which computational innovation and proprietary medicines continuously strengthen one another, creating differentiated therapies, valuable intellectual property, and new partnership opportunities. About PulmoSIM Therapeutics PulmoSIM Therapeutics LLC is a wholly owned subsidiary of VeriSIM Life focused on developing first-in-class inhaled therapeutics for pulmonary diseases with significant unmet medical need. Its lead program, PT001, is being developed for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, pulmonary fibrosis, and additional pulmonary indications. About VeriSIM Life VeriSIM Life is an AI-enabled biotechnology company advancing drug development through its proprietary BIOiSIM platform. BIOiSIM combines mechanistic biosimulation with explainable artificial intelligence to predict drug behavior across pharmacology, efficacy, safety, and human translation, enabling more informed development decisions and accelerating the development of safer, more effective medicines. Theresa Bibeau VeriSIM Life +1 415-322-3125 marketing@verisimlife.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Zydus Lifesciences has launched REVAHALE (Revefenacin), India’s first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). REVAHALE is the first and only LAMA available in India that combines once-daily dosing with nebulised administration, offering a new treatment option for COPD patients who require nebulised therapy. Designed to provide sustained 24-hour bronchodilation with a single daily dose, REVAHALE addresses important challenges associated with inhaler-dependent therapies, particularly among elderly patients and those with severe respiratory impairment. COPD remains a significant public health challenge in India and is a leading cause of morbidity and mortality. While inhaled bronchodilator therapies have transformed disease management, many patients continue to experience difficulties using handheld inhalers, cognitive limitations, severe breathlessness, or an inability to generate sufficient inspiratory effort for effective drug delivery. REVAHALE has been developed to address these unmet needs through a convenient nebulised delivery platform that reduces dependence on inhalation technique and inspiratory flow. The therapy is compatible with standard jet nebulisers, providing flexibility and ease of use for patients and caregivers.